Simplify Logo
Johnson & Johnson

Johnson & Johnson

Global healthcare company offering pharma, devices.

Manager Global UDI

Full-TimePosted on 9/14/2026Deadline 9/21/26
$117k - $201.3k/yr

+ Long-term incentive program

Senior
Bachelor's
West Chester, PA, USA+2 more

More locations: Loughbeg, Ringaskiddy, Co. Cork, Ireland | Raritan, NJ, USA

Hybrid

Hybrid work is required; travel is up to 10–20% domestically and internationally.

About the job

Requirements
  • A bachelor's degree in Engineering, Life Sciences, Information Systems, or a related field is required.
  • Six to eight years of relevant experience in Quality Assurance, Regulatory Compliance, or Technology Quality within a regulated industry is required, with medical device experience strongly preferred.
  • Demonstrated experience with Unique Device Identification regulations and global regulatory frameworks, including FDA and EU MDR, is required.
  • Strong knowledge of quality systems, data governance, and computerized system validation is required.
  • Experience leading cross-functional, global initiatives in a matrixed organization is required.
  • Experience supporting audits and regulatory inspections is required.
  • Strong analytical, problem-solving, and risk-based decision-making skills are required.
  • Excellent written and verbal communication skills are required.
  • English language proficiency is required.
  • Travel availability of up to 10–20% domestically and internationally is required.
Responsibilities
  • Lead and govern the global Unique Device Identification program, ensuring compliance with FDA, EU MDR, and other applicable international Unique Device Identification regulations.
  • Own Unique Device Identification-related quality processes, procedures, and controls, ensuring alignment with standards.
  • Partner with information technology and digital teams to ensure Unique Device Identification system design, validation, data integrity, and ongoing system compliance.
  • Provide quality oversight for Unique Device Identification data management, including master data accuracy, change control, and issue remediation.
  • Lead cross-functional collaboration with Regulatory Affairs, Supply Chain, Manufacturing, Research and Development, and Commercial teams to ensure end-to-end Unique Device Identification execution.
  • Support and participate in regulatory inspections, internal audits, and health authority interactions related to Unique Device Identification compliance.
  • Monitor global regulatory trends and translate new or evolving Unique Device Identification requirements into scalable business and quality processes.
  • Drive continuous improvement initiatives to enhance Unique Device Identification governance, efficiency, and compliance sustainability.
  • Provide coaching and leadership to team members and stakeholders to strengthen Unique Device Identification and quality capabilities across the organization.
Desired Qualifications
  • A master's degree in a scientific, technical, or business discipline is preferred.
  • Experience working with enterprise systems supporting Unique Device Identification and product data, such as enterprise resource planning, product lifecycle management, and labeling systems, is preferred.
  • Prior people-leadership or matrix-leadership experience is preferred.
  • Experience within orthopedics or complex medical device portfolios is preferred.
  • Familiarity with global supply chain and labeling processes is preferred.
  • Change management or continuous improvement experience in regulated environments is preferred.
  • Additional language proficiency is a plus.
  • ASQ, RAC, or equivalent quality/regulatory certification is preferred.

About the company

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • J&J raised 2026 sales guidance to $101.1 billion after July 15, 2026 results.
  • TREMFYA delivered 71% growth in Q2 2026 and its first $2 billion quarter.
  • Apollo’s September 2026 interest in DePuy Synthes validates a near-$20 billion asset value.

What critics are saying

  • Talc litigation persists; Reuters reported a February 13, 2026 Pennsylvania loss and September 2026 settlement pressure.
  • DePuy Synthes talks with Apollo on September 11, 2026 expose $9.3 billion MedTech revenue to breakup risk.
  • STELARA’s biosimilar erosion still drags growth; another pipeline miss would expose J&J’s valuation.

What makes Johnson & Johnson unique

  • J&J’s 2025 revenue reached $94.2 billion across pharmaceuticals, MedTech, and consumer heritage.
  • Innovative Medicine holds 28 billion-dollar products, reducing dependence on any single franchise.
  • TREMFYA, Carvykti, and Darzalex give J&J multiple blockbusters beyond STELARA.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 18th, 2026
J&J stock trades at 28x earnings, but STELARA biosimilar hit distorts valuation

Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.

Yahoo Finance
Sep 14th, 2026
Apollo in talks to acquire J&J's orthopedics unit for $20B

Johnson & Johnson shares rose 1.3% in pre-market trading following reports that Apollo Global Management is in discussions to acquire its orthopedics business for approximately $20 billion. Bloomberg News reported the potential deal could be finalised within weeks, citing people familiar with the matter. The orthopedics division generated $9.3 billion in revenue in 2025. However, the business has faced thousands of lawsuits related to its hip replacement devices. No transaction has been confirmed. Investors responded positively to news of the reported discussions and the potential valuation of the orthopedics unit.

Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.